HomeEVGN • NASDAQ
add
Evogene Ltd
$0.79
Makalipas ang Oras ng Trabaho:(2.72%)+0.021
$0.81
Sarado: Mar 5, 6:00:01 PM GMT-5 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$0.84
Sakop ng araw
$0.73 - $0.84
Sakop ng taon
$0.73 - $2.42
Market cap
6.84M USD
Average na Volume
835.28K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 312.00K | -82.63% |
Gastos sa pagpapatakbo | 2.88M | -64.76% |
Net na kita | 3.87M | 150.77% |
Net profit margin | 1.24K | 392.27% |
Kita sa bawat share | -0.46 | 64.51% |
EBITDA | -2.44M | 64.22% |
Aktuwal na % ng binabayarang buwis | -0.04% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 15.96M | -20.02% |
Kabuuang asset | 26.09M | -34.97% |
Kabuuang sagutin | 8.83M | -68.31% |
Kabuuang equity | 17.25M | — |
Natitirang share | 8.72M | — |
Presyo para makapag-book | 6.45 | — |
Return on assets | -22.70% | — |
Return on capital | -39.13% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 3.87M | 150.77% |
Cash mula sa mga operasyon | -3.33M | 32.37% |
Cash mula sa pag-invest | 10.91M | 441.12% |
Cash mula sa financing | -10.34M | -318.34% |
Net change in cash | -2.70M | -247.46% |
Malayang cash flow | -385.62K | -131.18% |
Tungkol
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
CEO
Itinatag
1999
Website
Mga Empleyado
117